Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo.

[1]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[2]  M. Prentki,et al.  Coordinate Regulation of Malonyl-CoA Decarboxylase,sn-Glycerol-3-phosphate Acyltransferase, and Acetyl-CoA Carboxylase by AMP-activated Protein Kinase in Rat Tissues in Response to Exercise* , 2002, The Journal of Biological Chemistry.

[3]  N. Ruderman,et al.  Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. , 1994, The American journal of physiology.

[4]  D. Hardie,et al.  The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. , 2002, Diabetes.

[5]  P. Geiger,et al.  Activation of p38 MAP kinase enhances sensitivity of muscle glucose transport to insulin. , 2005, American journal of physiology. Endocrinology and metabolism.

[6]  David Carling,et al.  The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[7]  N. Ruderman,et al.  Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. , 1997, The American journal of physiology.

[8]  G. Cooney,et al.  Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. , 2002, Endocrinology.

[9]  D. Hardie.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .

[10]  D. Hardie,et al.  AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. , 1998, The Biochemical journal.

[11]  Vincent Lebon,et al.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.

[12]  J. Sturis,et al.  Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. , 1996, The American journal of physiology.

[13]  H. Lodish,et al.  Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl–CoA carboxylase inhibition and AMP-activated protein kinase activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[15]  L. Orci,et al.  Lipoapoptosis: its mechanism and its diseases. , 2002, Biochimica et biophysica acta.

[16]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[17]  G. Cooney,et al.  AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. , 2002, Diabetes.

[18]  N. Ruderman,et al.  Malonyl coenzyme A and adiposity in the Dahl salt-sensitive rat: effects of pioglitazone. , 1996, Metabolism: clinical and experimental.

[19]  E. Kraegen,et al.  Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. , 2001, Biochemical Society transactions.

[20]  L. J. Hardies,et al.  Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.

[21]  B. Corkey,et al.  Regulation of free and bound magnesium in rat hepatocytes and isolated mitochondria. , 1986, The Journal of biological chemistry.

[22]  Demetrios Vavvas,et al.  Malonyl-CoA, fuel sensing, and insulin resistance. , 1999, American journal of physiology. Endocrinology and metabolism.

[23]  L. Orci,et al.  Diseases of liporegulation: new perspective on obesity and related disorders , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  H. Motoshima,et al.  Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. , 2003, Diabetes.

[25]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[26]  R. Coleman,et al.  AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. , 1999, The Biochemical journal.

[27]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-related Protein of 30 Kilodaltons by Ppar␥ Agonists: a Potential Mechanism of Insulin Sensitization , 2022 .

[28]  N. Ruderman,et al.  Glucose autoregulates its uptake in skeletal muscle: involvement of AMP-activated protein kinase. , 2003, Diabetes.

[29]  G. Dobson,et al.  Adjustment of K' to varying pH and pMg for the creatine kinase, adenylate kinase and ATP hydrolysis equilibria permitting quantitative bioenergetic assessment. , 1995, The Journal of experimental biology.

[30]  D. Hardie,et al.  AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. , 1999, American journal of physiology. Endocrinology and metabolism.

[31]  C. Burant,et al.  Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.